Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2014, Article ID 897249, 11 pages
http://dx.doi.org/10.1155/2014/897249
Research Article

Unraveling Natalizumab Effects on Deregulated miR-17 Expression in CD4+ T Cells of Patients with Relapsing-Remitting Multiple Sclerosis

Clinical Neuroimmunology, Departments of Biomedicine and Neurology, University Hospital Basel, Hebelstrasse 20, 4031 Basel, Switzerland

Received 28 November 2013; Accepted 28 March 2014; Published 12 May 2014

Academic Editor: Silvia Sánchez-Ramón

Copyright © 2014 Maria Meira et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. D. Trapp and K.-A. Nave, “Multiple sclerosis: an immune or neurodegenerative disorder?” Annual Review of Neuroscience, vol. 31, pp. 247–269, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. C. O'Gorman, R. Lucas, and B. Taylor, “Environmental risk factors for multiple sclerosis: a review with a focus on molecular mechanisms,” International Journal of Molecular Sciences, vol. 13, pp. 11718–11752, 2012. View at Google Scholar
  3. M. Ramanathan, B. Weinstock-Guttman, L. T. Nguyen et al., “In vivo gene expression revealed by cDNA arrays: the pattern in relapsing-remitting multiple sclerosis patients compared with normal subjects,” Journal of Neuroimmunology, vol. 116, no. 2, pp. 213–219, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. R. Bomprezzi, M. Ringnér, S. Kim et al., “Gene expression profile in multiple sclerosis patients and healthy controls: identifying pathways relevant to disease,” Human Molecular Genetics, vol. 12, no. 17, pp. 2191–2199, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. R. L. P. Lindberg and L. Kappos, “Transcriptional profiling of multiple sclerosis: towards improved diagnosis and treatment,” Expert Review of Molecular Diagnostics, vol. 6, no. 6, pp. 843–855, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. D. P. Bartel, “MicroRNAs: genomics, biogenesis, mechanism, and function,” Cell, vol. 116, no. 2, pp. 281–297, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. L. He and G. J. Hannon, “MicroRNAs: small RNAs with a big role in gene regulation,” Nature Reviews Genetics, vol. 5, no. 7, pp. 522–531, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. J. C. Carrington and V. Ambros, “Role of microRNAs in plant and animal development,” Science, vol. 301, no. 5631, pp. 336–338, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. H.-W. Hwang and J. T. Mendell, “MicroRNAs in cell proliferation, cell death, and tumorigenesis,” British Journal of Cancer, vol. 94, no. 6, pp. 776–780, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. A. M. Cheng, M. W. Byrom, J. Shelton, and L. P. Ford, “Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis,” Nucleic Acids Research, vol. 33, no. 4, pp. 1290–1297, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. C.-Z. Chen, L. Li, H. F. Lodish, and D. P. Bartel, “MicroRNAs modulate hematopoietic lineage differentiation,” Science, vol. 303, no. 5654, pp. 83–86, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. M. A. Lindsay, “microRNAs and the immune response,” Trends in Immunology, vol. 29, no. 7, pp. 343–351, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Ventura, A. G. Young, M. M. Winslow et al., “Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters,” Cell, vol. 132, no. 5, pp. 875–886, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. C. Xiao, L. Srinivasan, D. P. Calado et al., “Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes,” Nature Immunology, vol. 9, no. 4, pp. 405–414, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. L. Fontana, E. Pelosi, P. Greco et al., “MicroRNAs 17-5p-20a-106a control monocytopoiesis through AML1 targeting and M-CSF receptor upregulation,” Nature Cell Biology, vol. 9, no. 7, pp. 775–787, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. L. R. Corsini, G. Bronte, M. Terrasi et al., “The role of microRNAs in cancer: diagnostic and prognostic biomarkers and targets of therapies,” Expert Opinion on Therapeutic Targets, vol. 16, no. 2, pp. S103–S109, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. F. Ode Jr., C. S. Moore, T. E. Kennedy, J. P. Antel, A. Bar-Or, and A. S. Dhaunchak, “MicroRNA dysregulation in multiple sclerosis,” Frontiers in Genetics, vol. 3, p. 311, 2012. View at Google Scholar
  18. C. Fenoglio, E. Ridolfi, D. Galimberti, and E. Scarpini, “MicroRNAs as active players in the pathogenesis of multiple sclerosis,” International Journal of Molecular Sciences, vol. 13, pp. 13227–13239, 2012. View at Google Scholar
  19. D. Franciotta, M. Salvetti, F. Lolli, B. Serafini, and F. Aloisi, “B cells and multiple sclerosis,” The Lancet Neurology, vol. 7, no. 9, pp. 852–858, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. H. L. Weiner, “Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease,” Archives of Neurology, vol. 61, no. 10, pp. 1613–1615, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. G. De Santis, M. Ferracin, A. Biondani et al., “Altered miRNA expression in T regulatory cells in course of multiple sclerosis,” Journal of Neuroimmunology, vol. 226, no. 1-2, pp. 165–171, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. R. L. P. Lindberg, F. Hoffmann, M. Mehling, J. Kuhle, and L. Kappos, “Altered expression of miR-17-5p in CD4+ lymphocytes of relapsing-remitting multiple sclerosis patients,” European Journal of Immunology, vol. 40, no. 3, pp. 888–898, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. C. Sievers, M. Meira, F. Hoffmann, P. Fontoura, L. Kappos, and R. L. Lindberg, “Altered microRNA expression in B lymphocytes in multiple sclerosis: towards a better understanding of treatment effects,” Clinical Immunology, vol. 144, pp. 70–79, 2012. View at Google Scholar
  24. P. Iaffaldano, G. Lucchese, and M. Trojano, “Treating multiple sclerosis with natalizumab,” Expert Review of Neurotherapeutics, vol. 11, no. 12, pp. 1683–1692, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. T. Derfuss, J. Kuhle, R. Lindberg, and L. Kappos, “Natalizumab therapy for multiple sclerosis,” Seminars in Neurology, vol. 33, pp. 026–036, 2013. View at Google Scholar
  26. N. Tubridy, P. O. Behan, R. Capildeo et al., “The effect of anti-α4 integrin antibody on brain lesion activity in MS,” Neurology, vol. 53, no. 3, pp. 466–472, 1999. View at Google Scholar · View at Scopus
  27. R. A. Rudick and A. Sandrock, “Natalizumab: α4-integrin antagonist selective adhesion molecule inhibitors for MS,” Expert Review of Neurotherapeutics, vol. 4, no. 4, pp. 571–580, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. L. Kappos, P. W. O'Connor, C. H. Polman et al., “Clinical effects of natalizumab on multiple sclerosis appear early in treatment course,” Journal of Neurology, vol. 260, pp. 1388–1395, 2013. View at Google Scholar
  29. B. Weinstock-Guttman, S. L. Galetta, G. Giovannoni et al., “Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS,” Journal of Neurology, vol. 259, no. 5, pp. 898–905, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. R. L. P. Lindberg, L. Achtnichts, F. Hoffmann, J. Kuhle, and L. Kappos, “Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients,” Journal of Neuroimmunology, vol. 194, no. 1-2, pp. 153–164, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. R. Gogada, N. Yadav, J. Liu et al., “Bim, a proapoptotic protein, up-regulated via transcription factor E2F1-dependent mechanism, functions as a prosurvival molecule in cancer,” The Journal of Biological Chemistry, vol. 288, pp. 368–381, 2013. View at Google Scholar
  32. S. Jiang, C. Li, V. Olive et al., “Molecular dissection of the miR-17-92 cluster's critical dual roles in promoting Th1 responses and preventing inducible Treg differentiation,” Blood, vol. 118, no. 20, pp. 5487–5497, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. Z. Li, C.-S. Yang, K. Nakashima, and T. M. Rana, “Small RNA-mediated regulation of iPS cell generation,” EMBO Journal, vol. 30, no. 5, pp. 823–834, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Trickett and Y. L. Kwan, “T cell stimulation and expansion using anti-CD3/CD28 beads,” Journal of Immunological Methods, vol. 275, no. 1-2, pp. 251–255, 2003. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Junker, R. Hohlfeld, and E. Meinl, “The emerging role of microRNAs in multiple sclerosis,” Nature Reviews Neurology, vol. 7, no. 1, pp. 56–59, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Waschbisch, M. Atiya, R. A. Linker, S. Potapov, S. Schwab, and T. Derfuss, “Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis,” PLoS ONE, vol. 6, no. 9, article e24604, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. F. Petrocca, A. Vecchione, and C. M. Croce, “Emerging role of miR-106b-25/miR-17-92 clusters in the control of transforming growth factor β signaling,” Cancer Research, vol. 68, no. 20, pp. 8191–8194, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Jiang, C. Li, V. Olive et al., “Molecular dissection of the miR-17-92 cluster's critical dual roles in promoting Th1 responses and preventing inducible Treg differentiation,” Blood, vol. 118, no. 20, pp. 5487–5497, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. M. O. Li, Y. Y. Wan, S. Sanjabi, A.-K. L. Robertson, and R. A. Flavell, “Transforming growth factor-β regulation of immune responses,” Annual Review of Immunology, vol. 24, pp. 99–146, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. M. O. Li, S. Sanjabi, and R. Flavell, “Transforming growth factor-β controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms,” Immunity, vol. 25, no. 3, pp. 455–471, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. L. Xu, A. Kitani, and W. Strober, “Molecular mechanisms regulating TGF-Β-induced Foxp3 expression,” Mucosal Immunology, vol. 3, no. 3, pp. 230–238, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. K. Venken, N. Hellings, M. Thewissen et al., “Compromised CD4+ CD25high regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level,” Immunology, vol. 123, no. 1, pp. 79–89, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. V. Viglietta, C. Baecher-Allan, H. L. Weiner, and D. A. Hafler, “Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis,” Journal of Experimental Medicine, vol. 199, no. 7, pp. 971–979, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. C.-Y. Li, L. Suardet, and J. B. Little, “Potential role of WAF1/Cip1/p21 as a mediator of TGF-β cytoinhibitory effect,” Journal of Biological Chemistry, vol. 270, no. 10, pp. 4971–4974, 1995. View at Publisher · View at Google Scholar · View at Scopus
  45. S. Ramesh, X.-J. Qi, G. M. Wildey et al., “TGFβ-mediated BIM expression and apoptosis are regulated through SMAD3-dependent expression of the MAPK phosphatase MKP2,” EMBO Reports, vol. 9, no. 10, pp. 990–997, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. L. O'Connor, A. Strasser, L. A. O'Reilly et al., “Bim: a novel member of the Bcl-2 family that promotes apoptosis,” EMBO Journal, vol. 17, no. 2, pp. 384–395, 1998. View at Publisher · View at Google Scholar · View at Scopus
  47. F. Petrocca, R. Visone, M. R. Onelli et al., “E2F1-regulated MicroRNAs impair TGFβ-dependent cell-cycle arrest and apoptosis in gastric cancer,” Cancer Cell, vol. 13, no. 3, pp. 272–286, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. K. A. O'Donnell, E. A. Wentzel, K. I. Zeller, C. V. Dang, and J. T. Mendell, “c-Myc-regulated microRNAs modulate E2F1 expression,” Nature, vol. 435, no. 7043, pp. 839–843, 2005. View at Publisher · View at Google Scholar · View at Scopus
  49. M. M. Juntilla and G. A. Koretzky, “Critical roles of the PI3K/Akt signaling pathway in T cell development,” Immunology Letters, vol. 116, no. 2, pp. 104–110, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. A. Suzuki, M. T. Yamaguchi, T. Ohteki et al., “T cell-specific loss of Pten leads to defects in central and peripheral tolerance,” Immunity, vol. 14, no. 5, pp. 523–534, 2001. View at Publisher · View at Google Scholar · View at Scopus
  51. R. H. Newton and L. A. Turka, “Regulation of T cell homeostasis and responses by pten,” Frontiers in Immunology, vol. 3, p. 151, 2012. View at Google Scholar
  52. N. Putzki, M. K. Baranwal, B. Tettenborn, V. Limmroth, and E. Kreuzfelder, “Effects of natalizumab on circulating B cells, T regulatory cells and natural killer cells,” European Neurology, vol. 63, no. 5, pp. 311–317, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. P. T. Walsh, J. L. Buckler, J. Zhang et al., “PTEN inhibits IL-2 receptor-mediated expansion of CD4+CD25+ Tregs,” Journal of Clinical Investigation, vol. 116, no. 9, pp. 2521–2531, 2006. View at Publisher · View at Google Scholar · View at Scopus
  54. J. L. Buckler, X. Liu, and L. A. Turka, “Regulation of T-cell responses by PTEN,” Immunological Reviews, vol. 224, no. 1, pp. 239–248, 2008. View at Publisher · View at Google Scholar · View at Scopus
  55. N. Noren Hooten, K. Abdelmohsen, M. Gorospe, N. Ejiogu, A. B. Zonderman, and M. K. Evans, “microRNA expression patterns reveal differential expression of target genes with age,” PLoS One, vol. 5, no. 5, article e10724, 2010. View at Publisher · View at Google Scholar · View at Scopus
  56. K. Woods, J. M. Thomson, and S. M. Hammond, “Direct regulation of an oncogenic micro-RNA cluster by E2F transcription factors,” Journal of Biological Chemistry, vol. 282, no. 4, pp. 2130–2134, 2007. View at Publisher · View at Google Scholar · View at Scopus